# mRNA technology and personalized cancer vaccine research

> Live situation record from CLSTR: https://clstr.news/situations/mrna-technology-and-personalized-cancer-vaccine-research
> Updated: 2026-10-25T05:16:15.000Z. Sources: 53. Developments: 2.

Recent medical research highlights significant progress in using messenger RNA (mRNA) technology to develop personalized cancer vaccines. These vaccines utilize a patient’s specific tumor mutations or neoantigens to train the immune system to distinguish cancer cells from healthy tissue.

Specific developments include reports of mRNA drugs like Daraxonrasib potentially doubling life expectancy for pancreatic cancer patients. In kidney cancer studies, patients with clear cell renal cell carcinoma experienced no recurrence over a three-year median follow-up.

Further clinical trials involving the mRNA-based vaccine Intismaran, developed by MSD and Moderna, have shown evolving results. Data from the Phase 3 INTerpath-001 clinical study, presented at the 2026 ESMO Congress in Madrid, involved 1,137 high-risk melanoma patients who had undergone surgical tumor removal. The study shows that adding the personalized vaccine, intismeran autogene, to pembrolizumab immunotherapy reduces the risk of melanoma recurrence or death by 42% and the risk of distant metastasis or death by 38%.

Data from a median follow-up of 24.6 months indicated that 82.2% of patients in the combination group remained recurrence-free, compared to 70.0% in the group receiving only standard immunotherapy. A sensitivity analysis showed that for patients who remained cancer-free for the first six months of treatment, the risk of recurrence or death was reduced by 58% in the combination group compared to the monotherapy group. The treatment involves nine doses administered at three-week intervals and is tailored by sequencing tumor DNA to identify up to 34 unique neoantigens.

While the clinical results are positive, Moderna shares experienced volatility following the data release as market reactions reflected investor expectations regarding the magnitude of the results.

## Claims

- The Intismeran vaccine reduces the risk of melanoma recurrence or death by 42% when used with Keytruda. (corroborated by 29 sources)
- The INTerpath-001 study included 1,137 patients with high-risk melanoma. (corroborated by 27 sources)
- The vaccine is developed using mRNA technology. (corroborated by 26 sources)
- The risk of cancer spread decreased by 38% according to the dataset. (corroborated by 20 sources)
- The combination therapy resulted in an 82.2% recurrence-free rate after two years. (corroborated by 11 sources)
- The Keytruda-only group had a 70.0% recurrence-free rate. (corroborated by 10 sources)
- Moderna shares fell by up to 25% to $181 following the release of detailed study data. (corroborated by 2 sources)

## Timeline

### 2026-10-25: Moderna and Merck mRNA melanoma vaccine reduces recurrence risk by 42%

A Phase III trial shows that Moderna and Merck's personalized mRNA vaccine, combined with pembrolizumab, reduces melanoma recurrence or death risk by 42% in high-risk patients.

50 sources. https://clstr.news/cluster/antonio-ferro-outlines-hpv-vaccination-strategy-to-eliminate-related-cancers

### 2026-10-04: mRNA technology and personalized vaccines drive cancer treatment breakthroughs

mRNA technology and personalized vaccines are driving breakthroughs in cancer treatment, showing potential to extend life expectancy and prevent recurrence in melanoma, pancreatic, and kidney cancers.

2 sources. https://clstr.news/cluster/mrna-technology-and-personalized-vaccines-drive-cancer-treatment-breakthroughs

---
Cite as: mRNA technology and personalized cancer vaccine research. CLSTR, https://clstr.news/situations/mrna-technology-and-personalized-cancer-vaccine-research